May 26, 2021

Press release

FluoGuide A/S publishes interim report for the period January – March 2021

Copenhagen, Denmark, 26 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) today releases its results for the period 1 January... [Read more]

May 18, 2021

Press release

FluoGuide has received green light to proceed to the next dose level with FG001 in the ongoing clinical phase I/II trial in patients undergoing surgical treatment of high grade glioma

Copenhagen, Denmark, 18 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]

May 12, 2021

Press release

FluoGuide has received approval to commence with FG001 in evening dosing in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 12 May 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Danish Medicines Agency... [Read more]

May 12, 2021

Press release

FluoGuide has completed a directed share issue raising SEK 75 million

Copenhagen, Denmark, 12 May 2021 – FluoGuide A/S (publ a developer of surgical precision solutions within oncology (“FluoGuide” or the “Company”)... [Read more]

May 11, 2021

Press release

FluoGuide intends to carry out a directed share issue of approximately SEK 75 million

Copenhagen, Denmark, 17:31 CEST, 11 May 2021 – FluoGuide A/S (publ), a developer of surgical precision solutions within oncology (“FluoGuide” or... [Read more]

April 8, 2021

Press release

FluoGuide has received green light to proceed to fifth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 8 April 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]

March 18, 2021

Press release

FluoGuide appoints new Certified Adviser

Copenhagen, Denmark, 18 March 2021 – FluoGuide A/S (“FluoGuide” or the “Company) appoints Svensk Kapitalmarknadsgransking AB as its new Certified Adviser.... [Read more]

March 9, 2021

Press release

FluoGuide acquires rights to photothermal therapy using FG001

Copenhagen, Denmark, 9 March 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the Company has acquired... [Read more]

February 17, 2021

Press release

FluoGuide gets green light to proceed to fourth dose level with FG001 in the ongoing clinical phase I/II trial in patients with high grade glioma

Copenhagen, Denmark, 17 February 2021 – FluoGuide A/S (“FluoGuide” or the “Company”) is pleased to announce that the dose escalation committee... [Read more]